In Canada, between 3,000 and 4,000 people are living with amyotrophic lateral sclerosis (ALS), a disease that remains ...
In Canada, between 3,000 and 4,000 people are living with amyotrophic lateral sclerosis (ALS), a disease that remains ...
A new study published in Scientific Reports indicates that amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) have an extremely high geographic association, even after controlling for ...
Amyotrophic lateral sclerosis (ALS) and other motor neuron diseases (MNDs) are major global causes of death. However, their global incidence, mortality, and disability-adjusted life years remain ...
Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that ...
Amyotrophic lateral sclerosis (ALS) is a widespread neurodegenerative disease caused by the loss of neurons that control movement. Although abnormal accumulation of proteins called TDP-43 accompanies ...
Our Phase 2 design reflects both the translational science and the realities of ALS by integrating validated biomarkers such as neurofilament light chain alongside clinically meaningful endpoints,” ...
Chicago, June 23, 2025 (GLOBE NEWSWIRE) -- The global amyotrophic lateral sclerosis treatment market is projected to grow from USD 724.5 million in 2024 to USD 1,234.5 million by 2033, reflecting a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results